Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

A Correction on: Newsom-Davis T, Melosky B, Heist RS, Lu S, Pasello G, Chen X, Stachowiak M, Lyfar P, Forcina A and Ramalingam SS (2026) TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. Front. Oncol. 15:1721624. doi: 10.3389/fonc.2025.1721624 The conflict of interest statement was erroneously given as "TN-D has participated in advisory boards with AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, EQRx, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Merck Sharpe & Dohme, Novartis, Novocure, Pfizer, Regeneron, Roche, Sanofi, and Takeda; has been an invited speaker for Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, EQRx, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Roche, and Takeda; and has been a steering committee member for AstraZeneca, Merck Sharpe & Dohme, and Roche. BM has participated in advisory boards with Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck, Novartis, Prizer, Regeneron, Roche, and Sanofi. RH has participated in advisory boards with Amgen, AstraZeneca, Daiichi Sankyo, Biohaven, Claim, Eli Lilly, Novartis, Regeneron, Sanofi, Merck, and Gilead; and has received research funding institutional from AstraZeneca, Daiichi Sankyo, Eli Lilly, Mirati, Novartis, Corvus, and Mythic. SL has acted in an advisory role for AstraZeneca, Pfizer, Hutchison MediPharma, ZaiLab, GenomiCare, Novartis, Yuhan Corporation, Menarini, Mirati Therapeutics Inc, Daiichi Sankyo, Inc., D3 Bio Limited, Simcere, Takeda and Roche; has been an invited speaker for AstraZeneca, Roche, and Hansoh; is a member of the board of directors for Innovent Biologics, Inc.; has received research grants from AstraZeneca, Hutchison, Bristol Myers Squibb, Heng Rui, BeiGene, Roche, and Hansoh; and has participated in a Speaker's bureau for AstraZeneca, Roche, and Hansoh. GP has participated in advisory boards for, received honoraria and speaker's fees from, and acted as a consultant for Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Merck Sharpe & Dohme, Novartis, Pfizer, and Roche; and has received unconditioned research support from AstraZeneca, Roche, and Merck Sharpe & Dohme. XC, MS, PL, and AF are employed by AstraZeneca. SR has received institutional funding for research support from Amgen, AstraZeneca,